CD26 is a widely distributed 110-kDa cell surface glycoprotein with known dipeptidyl peptidase IV (DPPIV; EC 3.4.14.5) activity in its extracellular domain (1) (2) (3) (4) (5) . This ectoenzyme is capable of cleaving amino-terminal dipeptides from polypeptides with either L-proline or L-alanine in position 2 (6) . On T cells, CD26 expression is preferentially restricted to the CD4+ helper/memory population (2) , and CD26 can deliver a potent costimulatory T-cell activation signal (7) . Crosslinking of CD26 and CD3 with solid-phase immobilized monoclonal antibodies (mAbs) can induce T-cell costimulation and interleukin 2 production by either human CD4+ T cells or Jurkat T-cell lines transfected with CD26 cDNA (7, 8) . The cDNA sequence of CD26 predicts a type II membrane protein with only six amino acids in its cytoplasmic region (8) , suggesting that in addition to DPPIV enzyme activity other signal-inducing molecules may be associated with CD26. There is evidence that CD26 interacts, presumably in its extracellular domain, with both CD45, a proteintyrosine-phosphatase, and adenosine deaminase, each of which is capable of functioning in a signal transduction pathway (9, 10) .
CD4+ lymphocytes in patients with acquired immunodeficiency syndrome (AIDS) have an intrinsic defect in their ability to recognize and respond to "recall antigens" some time before a reduction in the total number of CD4+ cells occurs (11, 12) . The response to recall antigens is clearly a property of CD4+CD26+ T cells, since this is the only helper population known to proliferate in response to soluble antigens and to induce both major histocompatibility complexrestricted cytotoxic T lymphocytes, capable of killing virally infected target cells and B cells to secrete immunoglobulins (2) . Each of these properties is a key to the host's response to viral infection. In this regard, a selective decrease in CD26+ T cells has been reported in human immunodeficiency virus type 1 (HIV-1)-infected individuals prior to a general decrease in CD4+ T cells (13, 14) . Moreover, Tat, a regulatory protein encoded by the HIV-1 genome (15), has been shown to suppress the response of human peripheral T cells to soluble antigens (16) . It has been suggested that Tat can bind to and partially inhibit DPPIV (17 MATERIALS AND METHODS Establishment of DPPIV Activity-Deficient Jurkat Transfectants. The Xba I DNA fragment which encodes the entire CD26 protein was subcloned into the Xba I site of pTZ19u (Bio-Rad) so that its 5' end was located proximal to the EcoRI site of the vector DNA (8) . With single-stranded DNA prepared from this plasmid as a template and the oligodeoxynucleotide 5'-GGCTGGGCATATGGAG-3' (which directs the substitution of alanine for the putative catalytic serine at position 630), as a primer, site-directed mutagenesis was performed by the method of Kunkel (21) . After the sequence was verified, the Xba I CD26 cDNA fragment was inserted between the HindIII and Xba I sites of the mammalian Abbreviations: DPPIV, dipeptidyl peptidase IV; HIV-1, human immunodeficiency virus type 1; mAb, monoclonal antibody.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. expression vector RcCMV (Invitrogen). Then, the Mlu I-Xba I cytomegalovirus promoter fragment was replaced with the HindIII-Xba I SRa promoter fragment derived from pSRa-26 (8) . The supplemented with 10%o fetal bovine serum, 2 mM L-glutamine, penicillin (100 units/ml), and streptomycin sulfate (100 mg/ml) and were induced to undergo apoptosis by incubation in medium containing 7C11, a mAb that recognizes CD95 (Fas/ Apo-1) antigen (23) . After treatment, 1 million cells in 2 ml of medium from each sample were stained for 10 min at 37°C with the bisbenzimidazole dye Hoechst 33342 (1 tug/ml) and centrifuged. The cell pellets were resuspended in 1 ml of cold phosphate-buffered saline containing propidium iodide (5 ug/ ml) and analyzed for the percentage of apoptotic cell death by flow cytometry (24 (19) , to determine the involvement of DPPIV enzyme activity and its functional relationship to the costimulatory activity of CD26, we established Jurkat transfectants which expressed wild-type CD26 and DPPIV enzyme activity-deficient (DPPIV-) mutant CD26 (19) . We have screened transfectants for high expression of CD4 and wild-type and mutant CD26, although mutant CD26-transfected cells expressed a lower density of CD26 antigen (Fig. 1) (20, 23, (27) (28) (29) . CD95 was strongly expressed on all three CD26 mutant Jurkat cells tested and on parental (CD26-) Jurkat cells (Fig. 3) . CD95 was weakly expressed on all three wild-type CD26+ (DPPIV+) Jurkat cells tested. In all experiments to date, we have noted a variable expression of CD95 on mutant CD26+ (DPPIV-) transfectants, but it has always been higher than that found on wild-type CD26+ (DPPIVI) transfectants. Next we examined the occurrence of anti-CD95-induced programmed cell death in the above transfected cell lines. For this purpose, cells were treated with anti-CD95 mAb at 0.25 yg/ml and 0.5 Mg/ml and percent cell death was assessed by flow cytometry. In a representative experiment (Fig. 4) , both doses of anti-CD95 antibody appeared to enhance apoptosis in mutant CD26+
(DPPIV-) cells, whereas wild-type CD26+ (DPPIV+) Jurkat transfectants and parental cells were more resistant to the induction of apoptosis. These results may help explain the sensitivity to cell death of mutant CD26+ Jurkat cells (D28) following HIV-1 infection. DISCUSSION Both CD26-parental and CD26+ mutant (DPPIV-) Jurkat T cells were readily infected by HIV-1 whereas wild-type CD26+ (DPPIV+) Jurkat T cells were more resistant to infection. In addition, mutant CD26-transfected Jurkat cells (D28) were more susceptible to programmed cell death following HIV-1 infection and expressed significantly more cell surface CD95 (Fas/Apo-1) antigen than did wild-type Jurkat cells. These findings suggest that DPPIV enzyme activity may play a role in programmed cell death and protection against HIV-1 infection.
Several reports have shown a selective decrease in the proportion of CD26+ cells among the CD4+ cell population in HIV-1 infected individuals prior to a general reduction in CD4+ T cells (13, 14) . One explanation to account for these findings is the proposal by Hovanessian and coworkers (18) that CD26 serves as an essential cofactor for HIV-1 entry. These authors showed that both CD26 and CD4 were required to render murine NIH 3T3 cells infectible by HIV-1. In addition, they demonstrated that entry of HIV-1 was inhibited by both CD4 and a specific mAb against CD26 (1F7) and by specific inhibitors of CD26/DPPIV. Although these activities seemed to parallel one another, earlier studies from our laboratory indicated that mAb 1F7 neither reacted with the catalytic site of DPPIV nor affected DPPIV enzyme activity (5, 19) . In addition, we have been unable to demonstrate that 1F7 binds directly to cell surface CD4, blocks the binding of anti-CD4 mAb, or binds to either immobilized recombinant CD4 or HIV envelope glycoprotein gp120 (data not shown). In addition, we found no evidence to support the view that gp120 either binds to or is a substrate for recombinant soluble CD26, arguing strongly against the suggestion that DPPIV has endopeptidase activity capable of cleaving the V3 loop of gp120 during HIV-1 entry. Moreover, it is clear from Table 1 that parental CD26-Jurkat cells can be infected with HIV-1 despite a lack of CD26 antigen expression or measurable DPPIV enzymatic activity. Others have shown that CD26 is not required for syncytium formation and some have been unable to confim Hovanessian and coworkers' studies (18) on viral entry (30) (31) (32) . Taken together, these data suggest that CD26 is not a necessary cofactor for HIV infection.
Unexpectedly, our results suggest that DPPIV enzyme activity confers relative resistance to HIV-1 infection. These results support earlier studies demonstrating a differential susceptibility of subsets of CD4 cells to HIV-1 infection (11, 12) . Although phytohemagglutinin (PHA)-stimulated peripheral blood lymphocytes that express both CD4 and CD26 can be infected with HIV-1, in our present experiments Jurkat transfectants with a comparable phenotype expressing wildtype CD26 were relatively resistant when compared with either the parental Jurkat cell lacking CD26 or the transfectants expressing mutant CD26. Further studies are needed to clarify the mechanisms responsible for this differential susceptibility to HIV-1 infection. Perhaps the distinction between wild-type CD26+ transfectants and PHA blasts is that the transfectants stably express very high levels of cell surface CD26/DPPIV whereas in PHA blasts both CD4 and CD26 can be readily modulated off the surface. It is also possible that the distinctions between our findings and those of Hovanessian and colleagues (18) could be attributable to different assay systems. Possibly both the noncatalytic and the DPPIV enzymatic sites of CD26 can still promote virus entry, but subsequent virus replication within cells is negatively regulated by DPPIV enzyme activity. Finally, the known roles of CD26/DPPIV in T-cell activation, signaling, and membrane function may also be key to viral replication (8, 9, 19, 33) .
In the asymptomatic phase of HIV infection, a diminished response to recall antigens and loss of the CD29+ CD45RO+ (memory) CD4+ cells have been amply demonstrated (11, 12) . The mechanism by which HIV infection inhibits selective immunologic function at this stage of the disease is still not fully resolved. One plausible explanation is the preferential infection with HIV-1 of the CD4+ memory (CD29+-CD45RO+) T cells, which are known to be responsive to recall antigens (34, 35) . More recently, Blazquez et al. (13) not only detected a selective loss of CD26+ T cells prior to a (25, 26) . Indeed, in vitro activation of mature T cells from asymptomatic, HIV-1-infected individuals by polyclonal activators, bacterial superantigens, or antibody to the T-cell antigen receptor readily induces apoptosis (36) (37) (38) . Even crosslinking of bound gpl20 to normal CD4+ T cells primes these cells for apoptosis through T-cell receptor signaling (39) . A more recent association of apoptosis and AIDS has been made through the demonstration that CD95 (Fas/Apo-1), a marker known to trigger apoptosis, was strongly expressed on T lymphocytes from HIV-1-infected individuals (40) . Although not detected on normal resting T cells, CD95 is expressed on and can induce apoptosis in activated T cells with a CD45RO+ helper phenotype (41) . These cells are also known to exhibit CD26 and participate in the response to recall antigens (2, 35) . We suggest that the HIV Tat protein can contribute to both diminished immune responsiveness and enhanced susceptibility to the induction of apoptosis through its binding to CD26. The HIV-1 Tat protein is known to be essential for transactivation of viral genes as well as for viral replication (15) and can also be detected in the sera of HIV patients (16, 17) . HIV-1 Tat has also been shown to suppress the response of human peripheral T cells to recall antigen in vitro (16, 17) , a property of the CD4+CD26+ T cell. More importantly, HIV-1 Tat protein can bind to CD26 and partially inhibit DPPIV enzyme activity (16) . As shown in Fig. 3 , we found not only that the CD95 molecule was strongly expressed on mutant CD26+ (DPPIV-) T-cell lines but that these CD26+ (DPPIV-) enzyme-deficient lines were highly susceptible to both HIV-1 infection and the induction of apoptosis. Our in vitro observations suggest an important role for CD26 in HIV infectivity and provide a clinically relevant mechanism to partially explain both the selective loss of CD4+ helper cells and helper cell function in asymptomatic HIV-infected patients.
